Business model
SUKO Nordic‘s core competencies are product-specific and include research collaborations with universities and partner companies, as well as agreements with raw material suppliers in South America.
Other parts are outsourced to trusted partners in production, packing and parts of sales and distribution.
We use both our research experience and market knowledge in the development of product concepts. Current health trends, expectations about consumer preferences and the increasing research in healthy aging are important parts in SUKO Nordic strategic R&D plans. SUKO Nordic‘s business emerged from a Scandinavian appreciation of rosehip as a healthy fruit that deserves much greater recognition.
Rosehip has been used in traditional medicine for centuries, especially because of its high content of Vitamin C.
Although rosehips are found in many parts of the world, the highest quality rosehips are sourced from Chile in South America. In certain southern regions of Chile, where the soil is poor and uncultivated, you can find rosehips—typically 2-3 different varieties—being collected in the wild by local residents.
Our values
- Natural and organic
- No additives
- All based on research
- 100% traceability and transparency
- Plantation cultivation
Our mission
Develop and market unique research-based natural products that contribute to a healthier aging for all from young to old.
Our story
We, Monica Takamiya Wik and Peter Kristoffersen, co-founders, first met in the mid-1990s in Germany at the Max Planck Institute for Plant Breeding Research in Cologne. We were both interested in plant science, particularly the molecular mechanisms underlying plant signaling and defense responses against pathogens. Our time at the Max Planck Institute, being part of this prestigious research community and working with colleagues from many different nationalities, inspired us to pursue international collaborations in their future endeavors.
This experience is also why, about ten years later in 2005, we decided to start our first company with an international focus. In the meantime, we got research experience in human health and human medicine from both the Technical University of Denmark and University of Copenhagen, as well as from the medical and biotech industry.
SUKO Nordic is our second company, where we have leveraged our previous experiences and integrated new technologies, placing a greater emphasis on research and development. This approach has allowed us to expand our product range and develop innovative product concepts.
Our interest in the role of the human gut microbiome for health began in 2018 with the development of a novel synbiotic product MaquiPro®. Currently, clinical trials for MaquiPro® are underway at Copenhagen University.
